Patient Advocate since 1977.

Leave a comment

Canadian exports of medical marijuana soar as producers seek overseas toehold

(This is the third article of a four-part series examining how Canadian cannabis companies are expanding globally. Part I was published Aug. 9 and Part II on Aug. 10. Part IV will publish Wednesday.)

By Matt Lamers

Canadian medical cannabis exports are surging, driven by licensed producers that are using overseas shipments as a way to establish local partnerships and gain a foothold in foreign markets.

In particular, exports of dried medical marijuana and MMJ oil products from Canada have soared since 2015.

And they are on pace to double this year from 2016 levels, according to data obtained by Marijuana Business Daily. Analysts expect this trend to continue in the near future as more countries legalize medical cannabis.

While exports remain a sliver of overall medical marijuana sales in Canada, licensed producers (LPs) have moved to capitalize on burgeoning overseas MMJ markets such as Germany, Australia and South America.

According to data from Health Canada, the government body responsible for issuing cannabis export permits:

  • Just over 45 kilograms (100.3 pounds) of dried cannabis and 94.7 kilograms of cannabis oil were exported through July 20 of this year.
  • For all of 2016, 44.8 kilograms of dried cannabis and 100.8 kilograms of cannabis oil were shipped overseas.

No medical marijuana was exported in 2015 under the former Conservative government, which did not share the pro-MJ views voiced by current Prime Minister Justin Trudeau.

Cam Battley – a member of the board of directors of Cannabis Canada, the industry association for licensed producers – sees exports as a means to an end.

“We’re going to see exports to multiple new legal medical cannabis markets soar,” he said, “but ultimately the real game is going to be building and owning capacity in new markets.”

How it breaks down

Over the past two years, Canadian LPs have exported cannabis oil to Australia, the Cayman Islands, Chile, Croatia, Cyprus, the Czech Republic and New Zealand. Dried cannabis has been sent to Australia, Brazil, Germany, Israel and the Netherlands, according to Health Canada.

No cannabis export permits were issued in 2015, while 43 were handed out last year and 75 as of July 20 this year.

Of the 75 permits issued this year, 11 were for dried cannabis and 64 for cannabis oil products.

In total, 118 export permits were issued by Health Canada as of July 20 under federal guidelines established between 2013 and 2016.

The data also shows that most export applications were approved.

In 2016, Health Canada received 11 export applications for dried medical cannabis and issued nine permits.

So far this year, Health Canada has approved 11 of 13 export applications submitted for dried MMJ.

Though growing quickly, exports still represent a tiny fraction of overall MMJ sales by the country’s licensed producers.

In the first three months of 2017, slightly less than 6,000 kilograms of dried medical cannabis were sold to 129,876 registered clients across Canada for medical use, meaning exports accounted for less than 1% of all sales.

Examples of Canadian exporters

To give their marijuana sales a shot in the arm, several Canadian licensed producers have turned to the export market:

More export growth anticipated

Looking ahead, analysts expect exports will continue to rise as Canadian LPs service niche markets and establish localized operations abroad.

Khurram Malik, a partner with financial advisory firm Jacob Capital Management, sees exports spiking to certain nations and regions before coming back down once Canadian LPs set up operations in those markets.

“Exports will be larger from where they are today, but I don’t think they will be a large part of the revenue mix (for Canada’s LPs) going forward,” he said, owing to the high costs of growing cannabis in Canada. “Canada won’t be cost competitive with markets overseas for exports.”

Battley, the Cannabis Canada board member, sees exports climbing in response to new markets coming online. Twenty-three countries have active medical cannabis laws, while another 14 countries have pending laws, not counting the United States.

“What we’ve seen thus far is a trickle,” he added. “Germany’s intention, for example, is to have licensed producers from other jurisdictions supply the market until 2019, hoping that by then there will be sufficient domestic capacity. But building and licensing high-quality capacity takes time.”

Matt Lamers can be reached at mattl@mjbizdaily.com

Daily News | Canada Marijuana News | Cultivation | Featured

Leave a comment

CHONG’S CHOICE CBD – by Diamond CBD, Inc.

PotNetwork Holding Inc. (OTC: POTN) announced that Tommy Chong, counter-culture legend, marijuana legalization advocate and half of the incomparable creative team of Cheech & Chong, has selected its subsidiary, Diamond CBD, Inc., as his partner to introduce a proprietary brand of hemp-derived CBD oil products, under the brand name, Chong’s Choice CBD. Tommy’s brand will include CBD-infused edibles, concentrated solvent-free vaping additives and hemp oil tincture drops. Production of the new line is expected to begin within a month, with immediate online availability. As Tommy’s partner, Diamond CBD will offer the new brand to its distribution channels and assist in overall marketing. Tommy Chong stated, “I use Diamond CBD products and love them. They help me relax and often soothe the occasional pain of an old stoner.” He continued, “I want to be part of this 21st century CBD revolution which promises unprecedented health benefits to millions of people and Diamond CBD has a premier line of products, many of which I am pleased to bring to the market under my brand.”

Gary Blum, Chief Executive Officer, PotNetwork Holding, added, “We are honored to get to work closely with Tommy, and anticipate this partnership will further solidify Diamond CBD as the category leader in beneficial CBD products.”





Leave a comment

Is There a Medical Cannabis Crisis Brewing in Germany? By Marguerite Arnold

A looming product shortage, regulatory bureaucracy and insurance issues create a maelstrom of woes for German medical cannabis patients.

There is a great deal to be happy about with medical cannabis legalization in Germany. This is the first country that has mandated insurance coverage of the drug – at least at the federal legislative level.

However, as the government evaluates the finalists in the first tender bidfor domestically grown and regulated cannabis, a real crisis is brewing for patients on the ground. And further one that the industry not only sees but is trying to respond to.

Spektrum Cannabis GmbH, formerly MedCann GmbH began trying to address this problem when they obtained the first import license for Canadian cannabis last year. They are also one of the apparent five finalists in the pending government bid to grow the plant domestically for medical purposes. According to Dr. Sebastian Schulz, head of communications for Spektrum, “Shortly after the new cannabis law was reformed we experienced a huge increase in demand from the side of patients. We had prepared for that. The German population is very curious about cannabis as a medicine and in general very open to natural remedies.”

People are curious here. But like other places, the law in Germany has evolved slowly. Much like Israel, the government has allowed a trickle of patients to have access to cannabis by jumping through multiple, time consuming hoops. The process of getting cannabis prescribed, much less getting a pharmacy to stock it, was difficult. Patients had to pay out of pocket – a monthly cost of about $1,700. While that is expensive by American standards, to Germans, this is unheard of. The vast majority of the population – 90% – is on public health insurance. That means that most Germans get medications for $12 a month, no matter what they are. Allegedly, German patients were supposed to get about 5oz a month for this price. At least that is what the law says.

People are curious here. But like other places, the law in Germany has evolved slowlyAs in other countries, no matter what Germans think about recreational reform, the clear majority of them at this point support medical use. And at this point, both legislatively and via the courts, the government has said and been required to provide the drug to Germans patients at low cost.

Unintended Effects & Consequences

Since the law went into effect in March of this year however, things have suddenly turned very dire for patients.

The handful of people who had the right to grow at home – established under lawsuits several years ago – were suddenly told they could no longer do so. They had to go to a doctor and regular pharmacy. Even regular patients in the system found that their insurance companies, allegedly now required to pay, are refusing to reimburse claims. Doctors who prescribed the drug were abruptly informed that they would be financially responsible for every patient’s drug cost for the next two years (about $50,000 per patient).

Photo: Ian McWilliams, Flickr

To add a final blow to an already dire situation, German pharmacies that carried the drug, then announced an additional fee. It is about $9 extra per gram, added at the pharmacy, pushing the price of legitimate cannabis north of $20 dollars per gram. This is justified as a “preparation fee.” Cannabis bud is technically marked as an “unprocessed drug.” This means the pharmacies can charge extra for “processing” the same. In reality this might be a little bud trimming. If that. The current distributors in the market already prep and pre-package the drug.

What this bodes for a future dominated by infused products, oils and concentrates is unclear. However the impact now is large, immediate and expensive in a country where patients also must still go to the pharmacy in person for all prescription drugs.

There is no mail order here, by federal law. Online pharmacies are a luxury for Auslanders.

At minimum, this could mean that without some relief, German patients will go right back into the black market and home grow.While nobody has challenged this situation yet en masse, it is already a sore point not only for patients but across the industry. It means that an already expensive drug has gotten even more expensive. It also means that the government regulations are not working as planned.

At least not yet. For the large Canadian companies now coming into the market with multimillion-dollar investments already sunk in hard costs, Germany will be a loss-leader until the system sorts itself out.

According to Schulz, whose company is now in the thick of it, the new law is very vague. “Currently, there are almost no cannabis flowers available in German pharmacies because companies like us are not allowed to sell them,” says Schulz. “Various different regulatory demands come up that seemed to change on a monthly basis. We are ready to deliver even large amounts of cannabis for a market that might well explode soon – but we first need to overcome the regulatory nightmare that leads to the suffering of so many patients here these days.”

At minimum, this could mean that without some relief, German patients will go right back into the black market and home grow. Black market costs for cannabis are about $10-15 a gram. In other words, exactly the situation the government was hoping to avoid.

What Is Causing The Situation?

The intended effect of the legislation was twofold, according to industry insiders: To legalize cannabis in such a way to meet a rising public demand and, in the face of a court decision, to limit the home grow movement. The latter of which, despite federal regulations, is thriving here. Germans like to grow things, and cannabis is a rewarding plant to nurture.

High attendance at the Mary Jane Grow Expo in Berlin in June is just one sign that the genie is out of this particular bottle. BfArM – the federal agency in charge of regulating narcotics and medical devices – cannot stuff it back.Patients are going back to the way things were

However home grow does not build a professional, high volume cannabis market, much less a highly regulated medical one make. The government also made clear that it is going to have strict inspections and quality controls, and will technically buy all the cannabis produced, per the terms of the bid application process.

However, it is not entirely clear when the government will start actually doing the buying. And why the buying has not started yet. If insurance companies are refusing to pay, this means the government is not reimbursing them. The same government, which has also agreed to do so, as of March 2017.

What Gives On Good Old German Efficiency?

On the streets, patients are going back to the way things were. Many are used to fighting for the only drug that makes them feel better. The euphoria in May, for example, has been replaced with weary acceptance that things might get a bit worse before they really improve.

That said, there is also a realization that more activism and lobbying are required on just about every front. If an extrapolation of data from say Colorado or California is applied to Germany, there are already at least a million eligible patients here, based on the qualifying conditions. The government is planning for an annual increase in medical patients of about 5-10,000 a year, including in the amount of cannabis they are planning on buying from the licensed producers they choose. The numbers, however, are already not matching.Even existing patients are literally being forced into the black market again.

Added to this wrinkle is the other reality that is also looming, particularly now.

With one exception, all of the firms now apparently in contention as finalists for the German government bid will also be supplying a domestic market in Canada that is going rec next summer. One year, in other words, before the German companies even begin producing.

What Is The Upshot For Patients?

Guenther Weiglein is one of the five patients who sued for home grow rights in 2014. He is now suing again for the right to extend home grow privileges until the government figures out its process. He is not the only one. Earlier this year he was told he had to stop his home grow and integrate into the “mainstream” system. So far, he, along with other patients who are suing, including for insurance coverage, have not been able to get cannabis easily through the system, although they are starting to make progress.

Weiglein’s situation is made even more frustrating by the fluidity of the situation. As of late July, he had finally gotten agreement from his insurance company to cover the drug. But now he cannot find a doctor willing to accept the financial risk of prescribing it to him. And in the meantime he has no access to medication.

Talk to any group of advocates right now, and there is one ongoing story. Even existing patients are literally being forced into the black market again.

And those that can’t afford it? They are out of luck. Some patients say a tragedy like someone dying will create the impetus to move this into public eye. A hunger strike here by a leading cannabis doctor earlier this summer has so far not had much impact on policy. There is a great deal of pessimism here, as promised change earlier this year has turned into a long and drawn out multiyear question mark.

If this sounds like a bubbling and untenable situation, especially before a national election, it is. The prospect of another four years of Angela Merkel does not bode well for fast cannabis reform.

That said, the German government is now in an interesting situation. The law has now clearly changed to say that sick Germans are allowed to use cannabis as a drug of choice for chronic diseases when all else fails. Further, the national government has bound the insurance industry to cover it. So far, every patient who has sued for coverage has won. That has not, however, moved the insurance industry altogether. Nor has it solved the problem with doctors prescribing the drug.

Many now ask what will? It is clear, however, that it will change. The question is when, how fast, and in what situations.

The problem will undoubtedly ease by 2019, when the first German crops are finally ready, although it will be far from completely solved.


Leave a comment

The future of cannabis is vaping – by Marijuana News

The days of rolling joints are coming to an end. In 2017, more and more people are choosing to consume marijuana electronically.

Just like so many things about life in the post-smartphone world, cannabis is being made more convenient and accessible through modern technology. Rather than buying cannabis, rolling a joint, and burning plant matter, more and more people are turning to vaping — a far easier, more modern way to consume cannabis. You simply purchase plant matter or a small cartridge of oil (depending on the vaping device), load it into an inexpensive pen, and you’re ready to go.

The Bloom Farms “Highlighter” is a simple, inexpensive vape pen that can be used with exchangeable cartridges.Bloom Farms

As laws allowing adult cannabis use continue to pass in states across the US, cannabis oils, in particular, have increased in popularity — and they’re sure to continue on that path. It’s easy to see why: They’re inexpensive, easy to use, and discreet. In California, the largest state economy in the US, companies like Bloom Farms and Dark Heart are pioneering leaders in the cannabis oil market. Their products look just like the easy-to-use, crowd-friendly vaporizers seen above.

But what in the world is cannabis oil? How is it made? Is it safe? Here’s what we know about cannabis oils, the future of mainstream cannabis use.

How do you “vape” cannabis? A woman uses an electronic vaporizer with cannabidiol (CBD)-rich hemp oil while attending the International Cannabis Association Convention in New York.Eduardo Munoz/Reuters

There are two primary ways to vape cannabis: Vaping cannabis oil, or vaping cannabis itself.

Companies like Pax offer devices for vaping plant matter — you insert a small amount of crumbled cannabis into the device and it heats up just to the point of burning psychoactive components like THC. Those are popular, but far more popular are devices that vaporize cannabis oil — sold in disposable cartridges, easy to carry, and none of the hassle.

There are several different devices for vaporizing cannabis oil, but the most common is the vape pen you see above. It’s a simple, disposable device that can be used with simple, disposable cannabis oil cartridges. The pen component recharges via USB (or plugs into a wall with a USB adapter), and charges often last for at least one day.

Due to the universality of cannabis oil cartridges, they can be plugged in to most tobacco vaporizers — if you want to use your own rig for whatever reason, you likely can.

In the case of the standard vape pen, there is no concept of “on” or “off.” You simply pull from the mouthpiece of the pen and it lights up, slightly heating the oil and enabling you to inhale cannabis oil vapor.

What is cannabis oil? Bloom Farms

Instead of thinking of cannabis oil as a single product, think of it like a product category. Here’s how Bloom Farms CEO Michael Ray described cannabis oil in a recent interview with Business Insider:

“Cannabis oil is the essential oil of the plant. Much like lavender oil, or other essential oils, cannabis oil is extracted from the plant materials and that’s about it. It’s the essential oil of the cannabis plant.”

Ray is speaking to the direct product of extraction — as you might’ve guessed, cannabis oil is derived from the same plant matter that’s normally found inside of joints. Since there are different methods for extracting cannabis oil from cannabis plants, there are also many different results of different types of extraction.

What you get from any given provider of cannabis oil can differ greatly. Some cannabis oil makers blend their product with the oils of other plants (like peppermint or lavender); some makers only offer ultra-high potency oil, and some make a variety of options.

In the case of Bloom Farms, a popular brand in California, extraction means more than just distilling the main psychoactive ingredient (THC). Here’s Ray:

“There are thousands of elements. Everything that gives it any sort of flavor and smell (those are ‘terpenes’); in cannabis you have several cannabinoids (whether it be CBD, THC, THC-A, THC-B). It can turn into a very complex conversation. But what it is: It’s 100% cannabis oil, and in it is everything that makes up cannabis.”

What’s in cannabis oil? Dark Heart

Since cannabis oil is the derivative of cannabis plant matter, it contains many of the same elements. These include but are not limited to the following:

-Psychoactive properties, created by “cannabinoids” like THC.

-Terpenes (the millions of naturally-occurring chemicals that give cannabis its flavor and smell).

-Non-psychoactive cannabinoids like CBD.

In the case of a company like Dark Heart, which makes the Alchemy line of vape pens and vape pen cartridges, those elements are mixed with traditional aroma therapy essential oils like lavender and chamomile. Here’s Dark Heart marketing manager Savannah Hanks explaining how that works:

“For example: We have ‘Awaken,’ and this one is a Sativa [a type of cannabis]. But it’s also got known aromatherapy terpenes in it such as peppermint and lemongrass and citrus, which are known to be very energizing botanicals. So we combined that with a Sativa to make a very energizing experience when you consume the cannabis.”

The idea with a product like Alchemy from Dark Heart is that you’re buying an experience (“awaken”) rather than having to know about THC amounts of types of cannabis. Dark Heart also offers a more traditional high-potency oil if you’re looking for something more straightforward.

Traditionally, cannabis oils and other derivatives were made using petroleum-based solvents like butane. This is considered unsafe due to the explosive solvents used in production, and has been replaced by C02-based extraction methods in many cases.

“Some people use butane. Some people use propane. Some people use hexane. All of those ones I just mentioned are petroleum-based solvents that have the potential — when used in unsafe environments — to explode. We use strictly C02 because we feel it’s the safest, most efficient way to derive the oil,” Bloom Farms CEO Michael Ray told us.

The other benefit of C02, manufacturers told us, is it doesn’t leave behind any residual traces — a potential risk with petroleum-based solvents. “If produced incorrectly,” Ray said, “there can be residual butane left in the product.”

Is it safe? The Pax Era is a proprietary vape pen from the Pax company. It’s another option for vaporizing cannabis, albeit one that’s less open-source than the rest.Pax Labs

The spectre hanging over cannabis consumption — smoking, vaping, or otherwise — is the presumption of safety. The real answer to the question, “Is cannabis oil safe for consumption?” is “Nobody really knows.”

Bloom Farms CEO Michael Ray offered a good snapshot of how little we know: “Well, what I can say is that we feel…Common sense leads to low-temperature vaporization being exponentially safer than the inhalation of smoke.”

He’s not wrong — vaping does “feel” safer, both perceptually and in practice. “When I smoke cannabis, my respiratory system just doesn’t feel right,” he said. “I get inflammation in my respiratory system, it feels like to me. This is evident when I go to sleep at night — I don’t sleep well, and I’ll snore. With vaping, I don’t get any of those negative side effects that I get with smoking.”

That is, of course, anecdotal. There are no studies actually comparing the health effects of vaporizing cannabis oil with traditional cannabis consumption (smoking plant matter).

“Cannabis obviously has very limited data behind it as it is because of the inability to do any real testing in a professional setting,” Savannah Hanks of Dark Heart said. Her company, along with Bloom Farms, use third-party testing services like CW Analytical to assure their products are meeting the standards they set. But, even in California, there are no regulations governing what can and can’t be in cannabis oil.

How many people are using cannabis oil? Eaze

Cannabis oil cartridges are, unsurprisingly, really popular. Emerging from relative obscurity in just the last few years, cannabis oil cartridges are quickly gaining on bud sales in California. According to data collected by Eaze, a kind of Uber for weed that operates in California, cartridge sales have leapt from representing just 6% of overall product sales in 2015 to a whopping 24% in 2016.

In that same time period, sales of traditional cannabis dropped from representing nearly three quarters of all sales to around half. To say that vape cartridges are getting more popular by the day is to vastly undersell how rapidly they’re catching on with buyers.

There’s good reason for that, Ray said:

“The first reason that’s very obvious is the convenience. You don’t have the downsides of smoking — the smell, the need to carry around flower [bud], the need to find a way to consume it. Essentially the disruption of what it takes to smoke vs vape. It’s just very easy. It fits in your pocket, it doesn’t disturb the people around you, it doesn’t smell like cannabis. For a lot of people, especially the casual consumer, that’s very important.”

Another good reason cannabis oil vaping is so popular? It removes much of the traditional stigmas associated with buying and consuming cannabis. It’s a friendlier product than traditional cannabis, and it uses far less jargon in product descriptions.

“Maybe I need a mood enhancer,” Hanks said. “I have a really stressful day/life/career, and I need something that takes the edge off. I don’t have to be high, I just want to be ‘elevated’ (if you will). The vape pen cartridge is more of the mainstream for that group.”






Leave a comment

Tommy Chong rumored to be re-appearing at ICBC Berlin

ICBC Berlin - The BERLIN PEACE ACCORDS...putting an end to the world war on Cannabis!

ICBC BERLIN will be held April 12-13, 2018 in Berlin Germany.

Tommy Chong and his CHONGS CHOICE offerings http://chongschoice.us/ were well-received by the international cannabis executives this year and rumor has it he will be there again in 2018.

For more information on this HIGHLY RECOMMENDED event, please go to:


Leave a comment

10 Best Weed Strains For Cancer – Green Rush Daily

Research is discovering all the ways medical cannabis can help those dealing with cancer. Here are the best weed strains for cancer.

Most people have heard stories about the use of weed as a “miracle cure” for cancer. The truth may be a little less dramatic, but it’s just as exciting. Cancer patients’ use of medical cannabis continues to grow and diversify, thanks to groundbreaking research. Where once cancer patients turned to cannabis to combat symptoms related to their cancer treatments, like nausea and pain, researchers have recently reported that cannabis can actually slow and even kill certain types of cancer cells. This list of the best weed strains for cancer takes all of these therapeutic uses into account.

Introduction: The Best Weed Strains For Cancer

Best Weed Strains For Cancer

Exciting new research has shown that cannabinoids can actually increase the effects of chemotherapytreatments for patients diagnosed with Leukemia, a blood cancer. Researchers in the UK found that the two major cannabinoids, THC and CBD, were both effective in combination with chemotherapy. But when they were used together, the effect improved dramatically. Similarly, pairing cannabis with other substances like coconut oil can increase weed’s overall medical effects.

Interestingly, these findings support the notion of the “entourage effect,” or the idea the cannabinoids work best in conjunction with one another and shouldn’t be isolated. So for example, some of the best weed strains for cancer are those that provide a high, balanced concentration of these two cannabinoids.

Currently, the most widespread and accepted use of cannabis as a cancer treatment is as what’s called an “antiemetic.” Cancer patients undergoing chemo and radiation therapy experience intense vomiting and nausea as side effects. And so they use cannabis to treat their vomiting and nausea. These cancer treatments can also be very painful. Now that you have a better sense of the research behind all this, here are the best weed strains for cancer.

10. Chemo (Indica)

Best Weed Strains For Cancer

Chemo’s origins stem from the University of British Columbia in Canada, which reportedly developed the aptly named strain as a remedy for the side-effects of chemotherapy. This pungent, woody strain may be harsh to hit. But it combines the body-relaxing pain relief of a heavy indica with a stomach-soothing element that knocks out nausea and stimulates appetite loss. One of the best weed strains for cancer treatment-related ailments.

9. Cookies and Cream (Hybrid)

Best Weed Strains For Cancer

Cookies and Cream is a hybrid cross of Starfighter and Girl Scout Cookies. It takes advantage of its multi-symptom medicinal properties to help cancer patients suffering from insomnia, nausea, and pain. It’s an award-winning strain that helps patients find long-lasting relief from their symptoms.

8. Super Lemon Haze (Sativa)

Best Weed Strains For Cancer

Symptoms of chemo and radiation therapy aren’t limited to nausea and pain. They also sap patients’ energy, making it hard to get through the day. Research has proven that a positive attitude is essential to making the most of cancer treatments. And Super Lemon Haze, a potent antiemetic sativa, also uplifts and energizes.

7. Sweet and Sour Widow (Indica)

Best Weed Strains For Cancer

With a balanced, 1:1 ration of CBD to THC, this medically-potent indica strain is a perfect example of the entourage effect’s therapeutic use. Sweet and Sour Widow isn’t the most psychoactive strain, which can help cancer patients throughout the day without making them feel too “stoned.”

6. Cannatonic (Hybrid)

Best Weed Strains For Cancer

Despite what the name implies, Cannatonic is more uplifting than a sedative. And that’s helped it gain a reputation as a flexible strain for medical and recreational use. The strain is typically reserved for treating muscle spasms and aches, as well as migraines. On top of this, the strain is also one of the best for treating anxiety, in addition to a number of other psychological symptoms. It’s a high-CBD strain with a CBD/THC ratio can span anywhere from 5:1 to 1:1. This makes Cannatonic one of the best strains for the psychological aspects of cancer treatment.

5. Pennywise (Indica)

Best Weed Strains For Cancer

You might recognize the namesake of this high-CBD indica strain that blends Harlequin and Jack the Ripper. It’s the name Steven King gives to the terrifying clown in “It.” But don’t let the name put you off. This strain is packed with therapeutic CBD and an even complement of THC, making it one of the best strains for cancer symptoms.

4. Charlotte’s Web (Hybrid)

Best Weed Strains For Cancer

Growers specifically bred Charlotte’s Web to yield ultra-high CBD concentrations with negligible THC content. A uniquely medical strain, Charlotte’s Web is one of the most popular CBD-only strains in existence among the medical weed community. Genetically, Charlotte’s Web is derived from hemp. Thus, it has virtually no THC, and so users experience slim to no psychoactive effects.

3. Critical Mass (Indica)

Best Weed Strains For Cancer

The high THC levels of Critical Mass accompany its rich CBD profile. An excellent medical strain for pain relief, the cannabinoid content of this strain make it one of the most promising for inhibiting the growth of cancer cells themselves.

2. ACDC (Hybrid)

Best Weed Strains For Cancer

ACDC is a super-CBD strain with a 20:1 ratio with THC. As a daily medicinal strain, ACDC excels at treating nerve pain without any of the psychoactive effects of higher-THC strains. Without any intoxication, cancer patients can find relief from the many negative symptoms of their treatments, while also benefiting from CBD’s potential to curb cancer cell growth.

1. Remedy (Indica)

Best Weed Strains For Cancer

Remedy offers the highest CBD content of any indica out there, all with virtually zero THC-induced psychoactive effects. The CBD/THC ratio can reach up to 15:1. Cancer patients also report a sense of well-being after using this strain. Remedy excels at treating pain caused by nerve inflammation, as well as easing stress and reducing anxiety. It’s an excellent all-around strain for the many facets of cancer.

Adam Drury
Adam is a staff writer for Green Rush Daily who hails from Corvallis, Oregon. He’s an artist, musician, and higher educator with deep roots in the cannabis community. His degrees in literature and psychology drive his interest in the therapeutic use of cannabis for mind and body wellness

Leave a comment

Canadian cannabis M&As ready to ‘go crazy’: Q&A with Aurora CFO Glen Ibbott

July 12, 2017     


By Omar Sacirbey

Glen Ibbott had a successful career as a top executive with U.S. life sciences companies worth hundreds of millions of dollars that listed on the Nasdaq Stock Market.

But it wasn’t hard for Canada’s Aurora Cannabis to recently lure Ibott north of the border to become the medical marijuana producer’s chief financial officer.

Canada is preparing to launch an adult-use industry in 2018. And Ibott liked the idea of working in a country where companies are pioneering the global cannabis market.

He was also drawn by the explosion of merger and acquisition activity in Canada and Alberta-based Aurora’s plans to trade on the Toronto Stock Exchange.

Ibott, who became Aurora’s CFO in May, spoke with Marijuana Business Daily about IPOs, Canadian cannabis M&As and being a part of history.

What are the priorities you started with?

On the M&A side, because of our position – with the market cap and the balance sheet that we’ve got – we’re starting to see a lot of opportunities both domestically and internationally that we need to go after hard and fast.

We’re also listed on the TSX Venture Exchange (trading as ACB) – which is the junior exchange of the Toronto Stock Exchange – and we want to be listed on the senior board (Toronto Stock Exchange).

There are a lot more financial controls and diligence, and it helps if you’ve been through it. They’ve got a good team here, but they need more hands to get ready for that move to the TSX.

Where do you want to make acquisitions?

We just invested in an IPO in Australia called the Cann Group, going in at 19.9%, and we hope to see that develop into something more than just a financial investment. It’s there and Europe, and perhaps Israel.

The international space is intriguing, and there are some really good opportunities there. We’re looking at lots of stuff in Canada as well.

How do you prepare yourself for an M&A deal?

You need to be able to differentiate yourself, whether you’re first into the space or you’ve got a unique offering that can’t be easily replicated.

And you’ve got to look at the market and how you’re going to tell who’s going to be successful. And that will differ from country to country, depending on the regulatory regime.

Beyond that, you’ve just got to be prepared. This space is going to change so rapidly.

I think in the next few years, there will be a handful of big players and then a number of specialized businesses – almost like craft beer – and then all the others will get washed out.

They’ll get bought because they have reliable supply, or they have a unique offering that helps the company compete in the space. I think the M&A side of this is going to go crazy in the next couple of years.

Whether you want to get taken out or partner with somebody, you have to be prepared to move quickly. You need to have your financial and legal house in order.

In companies I’ve worked for, we’ve always had a data room ready, having all of our paperwork and tax returns ready. We have this prepared well before we even talk to anybody. You just make it part of your business to have these things up to date.

If you’re buying somebody, what are you looking for?

You want to make sure they don’t have any legal liabilities or that somebody is suing them. You want to understand how they compete in the space and why they’re different.

Nobody has the time or resources to do everything. But even keeping a couple of the fundamentals ready to go so if someone pops up and says, “Hey, we’re really interested in doing a deal or partnering with you; can you send some stuff over?”

It’s important to be prepared for that because a potential partner may not be able to wait for that for several months. They’ll move on to something else.

We plan to be very active, and I think there’s lots of opportunities. And from what I can see, our competitors are of the same mindset.

Why did you join the cannabis industry?

Why not? I spent most of the last 20 years in pharma and biotech, mainly publicly listed U.S. companies. They’re very dynamic, especially in smaller biotech, when you’re developing a lead drug and you’re going to live or die based on the success of that drug.

But when I looked at this industry, I basically thought this is a once-in-a-lifetime opportunity. How often do you see an industry where the demand is there, the governments are kind of starting to open up?

I haven’t ever seen an opportunity at this stage. It’s something you read in the history books, like a couple hundred years ago when guys were building railroads. It feels like you’re at the start of something big, and what’s ahead of us is just incredible.

The industry itself is really attractive, and when I looked at Aurora, you’ve got entrepreneurs who have a really solid track record of success. If you can show success, it’s more likely you can replicate it.

Plus, the company itself is really well positioned. Good market cap, just raised a bunch of money – I think we have the team and resources to really go after it.

It’s almost a no-brainer. Why wouldn’t you jump at this opportunity? I think the next few years are just going to be a blast.

This interview has been edited for length and clarity.

Omar Sacirbey can be reached at omars@mjbizdaily.com

Daily News | Canada Medical Marijuana News | Featured | Sales, Funding & Banking News